Karyopharm Therapeutics (KPTI) Non Operating Income (2013 - 2026)

Karyopharm Therapeutics (KPTI) has 13 years of Non Operating Income data on file, last reported at -$84.4 million in Q4 2025.

• Quarterly Non Operating Income fell 21635.97% year-over-year to -$84.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$105.3 million (down 344.41% YoY) and the FY2025 annual result came in at -$105.3 million, down 344.41% from the prior year.
• Non Operating Income slipped to -$84.4 million in Q4 2025, from -$17.9 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $52.0 million in Q2 2024 to a low of -$84.4 million in Q4 2025.
• A 5-year average of -$6.2 million and a median of -$4.7 million in 2021 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2024 — Non Operating Income surged 1874.03% — and 2025, when it tumbled 21635.97%.
• Tracing KPTI's Non Operating Income over 5 years: stood at -$8.4 million in 2021, then surged by 45.43% to -$4.6 million in 2022, then rose by 14.57% to -$3.9 million in 2023, then surged by 110.05% to $392000.0 in 2024, then plunged by 21635.97% to -$84.4 million in 2025.
• The last three Non Operating Income figures came in at -$84.4 million (Q4 2025), -$17.9 million (Q3 2025), and -$12.8 million (Q2 2025), per Business Quant data.